- Home
- ACAD vs COTY Comparison
ACAD vs COTY Comparison
Compare ACAD & COTY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACAD
- COTY
- Stock Information
- Founded
- ACAD 1993
- COTY 1904
- Country
- ACAD United States
- COTY United States
- Employees
- ACAD N/A
- COTY N/A
- Industry
- ACAD Biotechnology: Pharmaceutical Preparations
- COTY Package Goods/Cosmetics
- Sector
- ACAD Health Care
- COTY Consumer Discretionary
- Exchange
- ACAD Nasdaq
- COTY Nasdaq
- Market Cap
- ACAD 4.3B
- COTY 3.5B
- IPO Year
- ACAD 2004
- COTY 2013
- Fundamental
- Price
- ACAD $24.67
- COTY $4.16
- Analyst Decision
- ACAD Buy
- COTY Hold
- Analyst Count
- ACAD 21
- COTY 17
- Target Price
- ACAD $29.30
- COTY $5.77
- AVG Volume (30 Days)
- ACAD 1.8M
- COTY 13.3M
- Earning Date
- ACAD 11-05-2025
- COTY 11-05-2025
- Dividend Yield
- ACAD N/A
- COTY N/A
- EPS Growth
- ACAD 615.00
- COTY N/A
- EPS
- ACAD 1.33
- COTY N/A
- Revenue
- ACAD $1,018,885,000.00
- COTY $5,892,900,000.00
- Revenue This Year
- ACAD $14.01
- COTY $2.43
- Revenue Next Year
- ACAD $11.72
- COTY $3.66
- P/E Ratio
- ACAD $18.55
- COTY N/A
- Revenue Growth
- ACAD 14.41
- COTY N/A
- 52 Week Low
- ACAD $13.40
- COTY $3.67
- 52 Week High
- ACAD $26.65
- COTY $9.70
- Technical
- Relative Strength Index (RSI)
- ACAD 49.69
- COTY 42.62
- Support Level
- ACAD $23.34
- COTY $4.01
- Resistance Level
- ACAD $25.90
- COTY $4.53
- Average True Range (ATR)
- ACAD 0.78
- COTY 0.17
- MACD
- ACAD -0.28
- COTY 0.01
- Stochastic Oscillator
- ACAD 40.18
- COTY 56.40
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
About COTY Coty Inc.
Coty is a global beauty maker that generates 65% of sales from prestige beauty products (primarily fragrances) and 35% from mass makeup, skin care, and fragrance. For the fragrance business, Coty licenses luxury and high-end brands including Gucci, Burberry, Hugo Boss, Davidoff, and Calvin Klein. In contrast, its consumer cosmetics business focuses on acquired mass brands such as CoverGirl, Max Factor, Rimmel, Sally Hansen, and Bourjois. It also collaborates with social media celebrity Kylie Jenner to manage makeup products bearing her name. By region, Coty generates close to 48% of sales from Europe, 40% from the Americas, and 12% from Asia-Pacific. German investment firm JAB is a controlling shareholder, with a 54% stake as of June 2025.